Current options in antifungal pharmacotherapy.

Journal Article (Journal Article;Review)

Infections caused by yeasts and molds continue to be associated with high rates of morbidity and mortality in both immunocompromised and immunocompetent patients. Many antifungal drugs have been developed over the past 15 years to aid in the management of these infections. However, treatment is still not optimal, as the epidemiology of the fungal infections continues to change and the available antifungal agents have varying toxicities and drug-interaction potential. Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections.

Full Text

Duke Authors

Cited Authors

  • Mohr, J; Johnson, M; Cooper, T; Lewis, JS; Ostrosky-Zeichner, L

Published Date

  • May 2008

Published In

Volume / Issue

  • 28 / 5

Start / End Page

  • 614 - 645

PubMed ID

  • 18447660

International Standard Serial Number (ISSN)

  • 0277-0008

Digital Object Identifier (DOI)

  • 10.1592/phco.28.5.614


  • eng

Conference Location

  • United States